Abstract:1045 Objectives: The overall aim of this study was to validate I-131-PD-L1 SPECT tumor imaging and therapy, especially patients who has poor response to anti PD-L1 mAb therapy based on successful preparation of the probe with excellent stability. Methods: Anti-PD-L1(experimental probe) and IgG (control) were radiolabeled with iodine-131 (I-131-PD-L1, I-131-IgG) and were characterized in vitro, respectively. The stability of the probe and 4T1 cell up-taking after preparation of I-131-PD-L1 was prepared. Ability ofI-131-PD-L1 targeting to tumor was verified by bioditribution and SPECT, including blockade, I-131-IgG and I-131-PD-L1 (human). Expression of PD-L1 in tumor was tested by immunohistochemistry (IHC). To verify their therapeutic value, the study was recorded volume of tumor and their death in groups:I-131-PD-L1+ PD-L1 mAb, I-131-PD-L1, PD-L1 mAb and NS control. The side effects by I-131-PD-L1 and PD-L1 mAb were observed. Results: I-131-PD-L1 was successfully prepared and collected into EP tubes after purification by PD10 Column, with radiochemical yield (RCY): 80.21%±2.98% (n=5) and radiochemical purity (RCP): 96.51%±1.10% (n=5). The probe kept excellent stability with RCP>92% at 72 hours in vitro (n=6), RCP>90% in vivo at 24 hours and RCP>80% in vivo at 72 hours (n=3). The up-taking ratio peaked at 2 hours with 3.18%±0.86% (n=6). Ratio of T/M and T/B reached at 8.66±1.46 and 6.31±1.95 in biodistribution at 120 hours and I-131-PD-L1 in tumor was significantly suppressed (F=17.279, P=0.006) in blockade biodistribution. The breast tumor could be imaged by SPECT at 24 hours and the tumor gradually showed clearer at 48 hours and 72 hours post-injection and never be imaged in I-131-IgG (mouse), I-131-PD-L1 (blockade) and I-131-PD-L1 (human) at 72 hours. I-131-PD-L1+mAb could significantly suppress tumor growth than others groups; the median survivals of I-131-PD-L1+mAb was greatly longer than other groups, and the last one in combined therapy group survived till the 41st day which was better than mice in other groups. In the second PD-L1 mAb therapy (10 μg/g) which performed at 96 hours after the first mAb therapy (10 μg/g), we observed that 9/12 mice displayed serious adverse drug reaction of respiratory system, and died in 12 hours. Hepatorenal functions would keep normal at 7.4 MBq (200 μCi), but weight of mice dramatically descended due to poor appetite. Conclusions: I-131-PD-L1 could noninvasively monitor the expression of PD-L1 in breast tumor by SPECT scan. The probes could dramatically suppress tumor and prolong survival time. Key Words: SPECT; PD-L; Iodine-131; Theranostic probe; Molecular imaging

Synthesis and immunotherapy efficacy of a PD-L1 small-molecule inhibitor combined with its 131I-iodide labelled isostructural compound

Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy

Experimental Study on Radioiodine Labeled Anti-PD-L1 Monoclonal Tibody As Novel Tumor Immunosuppressive Agent Imaging Probe

In vitro and in vivo study on the treatment of non-small cell lung cancer with radionuclide labeled PD-L1 nanobody

1197 Site-specific Anti-Pd-1-irgd Peptide Conjugate Boosts Antitumor Efficacy Via Enhancement of T Cell Penetration and Engagement

Nuclear Imaging of PD-L1 Expression Promotes the Synergistic Antitumor Efficacy of Targeted Radionuclide Therapy and Immune Checkpoint Blockade

In situ vaccination and gene-mediated PD-L1 blockade for enhanced tumor immunotherapy

Immuno-SPECT/PET Imaging with Radioiodinated Anti-Pd-l1 Antibody to Evaluate PD-L1 Expression in Immune-Competent Murine Models and PDX Model of Lung Adenocarcinoma.

Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement

A novel anti-PD-L1/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity

[Combination therapy based on PD-1/PD-L1 blocking in the treatment of non-small cell lung cancer]

Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity

ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy

Construction of an Iodine-Labeled CS1001 Antibody for Targeting PD-L1 Detection and Comparison with Low-Molecular-Peptide Micro-PET Imaging

PD-L1 antibody conjugated dihydrotanshinone I-loaded polymeric nanoparticle for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death

Bifunctional molecular probe targeting tumor PD-L1 enhances anti-tumor efficacy by promoting ferroptosis in lung cancer mouse model

Nano-Liposome Co-Loaded with C-X-C Chemokine Ligand 12/CXCR4 Pathway Inhibitor Synergistically Increases the Immune Efficacy of Anti-PD-L1 and Increase Anti-Tumor Activity of Effector T Cells

Construction and preclinical evaluation of a 124I-labelled bispecific antibody targeting PD-L1 and PD-L2

Abstract LB098: Combination of a PD-1/CTLA-4 bispecific antibody with orally active PD-L1 inhibitor MAX-10181 effectively increased the percentage of tumors inhibited in animal model study

Dual targeting of TIGIT and PD-1 with a novel small molecule for cancer immunotherapy

Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap